Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.

Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2015 Jun;34(3):174-80. doi: 10.1089/mab.2014.0090.

PMID:
26090595
2.

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.

Kato Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.

Cancer Sci. 2014 Jun;105(6):744-8. doi: 10.1111/cas.12413.

3.

Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.

Liu X, Kato Y, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M.

Cancer Med. 2013 Dec;2(6):803-14. doi: 10.1002/cam4.149. Epub 2013 Oct 17.

4.

Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.

Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2013 Dec;32(6):377-81. doi: 10.1089/mab.2013.0050.

PMID:
24328739
5.

Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.

Kaneko MK, Tsujimoto Y, Hozumi Y, Goto K, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2013 Jun;32(3):224-8. doi: 10.1089/mab.2013.0006.

PMID:
23750482
6.

A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.

Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.

J Immunol. 2013 Jun 15;190(12):6239-49. doi: 10.4049/jimmunol.1300448. Epub 2013 May 20.

7.

Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.

Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y.

Biochem Biophys Res Commun. 2013 Mar 1;432(1):40-5. doi: 10.1016/j.bbrc.2013.01.088. Epub 2013 Jan 31.

PMID:
23376717
8.

Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin.

Kaji C, Tsujimoto Y, Kato Kaneko M, Kato Y, Sawa Y.

Acta Histochem Cytochem. 2012 Aug 30;45(4):227-37. Epub 2012 Jul 25.

9.

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.

Cancer Sci. 2012 Nov;103(11):1913-9. doi: 10.1111/j.1349-7006.2012.02385.x. Epub 2012 Aug 27.

10.

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.

Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A.

J Neurooncol. 2012 Jul;108(3):361-73. doi: 10.1007/s11060-012-0837-0. Epub 2012 Mar 7.

PMID:
22396072
11.

Podoplanin expression in advanced atherosclerotic lesions of human aortas.

Hatakeyama K, Kaneko MK, Kato Y, Ishikawa T, Nishihira K, Tsujimoto Y, Shibata Y, Ozaki Y, Asada Y.

Thromb Res. 2012 Apr;129(4):e70-6. doi: 10.1016/j.thromres.2012.01.003. Epub 2012 Jan 28.

PMID:
22283975

Supplemental Content

Loading ...
Support Center